Bifidobacterium infantis

Bifidobacterium infantis

What the trials found

Bifidobacterium infantis does not have enough research to establish relief of pain, bloating, urgency, or irregular bowel habits in women with irritable bowel syndrome.

  • 2 papers
  • 1 of 2 outcomes

What bifidobacterium infantis actually does

Outcome Effect Evidence Dose Time Rank
Early research 1
Ease irritable bowel syndrome symptoms Not enough research Irritable bowel syndrome can cause recurring belly pain and changes in bowel habits.
1 meta-analysis 1 papers · n=— 6 wk

Effect tiers come from native-unit MCID where available, Cohen's d otherwise.

Protocol

Dose, timing & forms

How much

The evidence is too limited to present a general IBS dose range as established. The useful starting point is to follow the label for a product that identifies its exact strain, since the clinical evidence comes from Bifidobacterium infantis 35624 rather than from B. infantis as a broad category.1

When and how long

Consistency matters more than chasing a particular time of day. The IBS trials used daily supplementation over weeks, so take a labeled strain regularly at a time you can stick with rather than using it only when symptoms flare.12

Forms & standardisation

Look for the full strain identifier, especially “35624,” rather than a front-label claim that lists only Bifidobacterium infantis. Probiotic research is strain-specific: the symptom result belongs to the tested 35624 preparation, not automatically to every capsule containing a related bacterium.1

In context

What this is and how it works

  • One study assessed IBS symptom relief, but sample size and measurable effect were not reported 1.
  • Two papers reviewed here spanned two outcomes, with evidence concentrated in women with irritable bowel syndrome.
  • Findings apply to strain-specific products, especially Bifidobacterium infantis 35624, not unspecified probiotic mixtures.

Bifidobacterium infantis is a type of beneficial bacterium that naturally belongs in the human gut, especially early in life. In supplements, the important detail is not just the species name. The IBS research tested a named strain, Bifidobacterium infantis 35624.1

IBS involves more than digestion. The gut and immune system can keep sending each other noisy alarm signals, which can amplify discomfort. In a clinical study, the 35624 strain shifted several immune messenger patterns toward balance, like turning down an oversensitive smoke alarm rather than muting the whole house.2

Bottom line

Bifidobacterium infantis 35624 is worth discussing with a clinician if IBS pain, bloating, urgency, or irregular bowel habits are persistent and you want a strain-specific probiotic trial. One study produced a promising result, but the evidence does not yet establish that it works broadly or predict who will respond.1 Skip vague products that do not name their strain, because the available finding cannot be transferred to them.1

Frequently asked

Common questions

Does Bifidobacterium infantis help IBS symptoms?

One clinical trial of the 35624 strain found lower overall IBS symptom scores, including less abdominal discomfort, bloating, and difficulty with bowel habits in women. That is encouraging, but one trial is not enough to establish a reliable result for everyone with IBS.1

How long does Bifidobacterium infantis take to work for IBS?

The available IBS research assessed symptoms after several weeks of daily use, not after a single dose. Give any trial enough time to judge a pattern, while remembering that the evidence remains early.1

Is every Bifidobacterium infantis probiotic the same?

No. Probiotics work at the strain level, much like different dog breeds share a species but do different jobs. The IBS trial tested Bifidobacterium infantis 35624, so its result does not automatically apply to products that list only the species name or a different strain.1

Sources

Sources

  1. 1. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome (2006)
  2. 2. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles (2005)

Generated August 27, 2026